Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-744-1340
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.05 million
Profitability
Miscellaneous
Employees76
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable
Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions
What is Syros Pharmaceuticals' stock symbol?
Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."
How were Syros Pharmaceuticals' earnings last quarter?
Syros Pharmaceuticals Inc (NASDAQ:SYRS) issued its earnings results on Tuesday, November, 12th. The company reported ($0.47) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.01. The business had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 86.92%. View Syros Pharmaceuticals' Earnings History.
When is Syros Pharmaceuticals' next earnings date?
What price target have analysts set for SYRS?
7 brokers have issued twelve-month price targets for Syros Pharmaceuticals' shares. Their forecasts range from $10.00 to $18.00. On average, they anticipate Syros Pharmaceuticals' stock price to reach $14.50 in the next year. This suggests a possible upside of 190.0% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.
What is the consensus analysts' recommendation for Syros Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.
Has Syros Pharmaceuticals been receiving favorable news coverage?
News headlines about SYRS stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Syros Pharmaceuticals.
Are investors shorting Syros Pharmaceuticals?
Syros Pharmaceuticals saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 2,590,000 shares, an increase of 8.8% from the September 30th total of 2,380,000 shares. Based on an average daily volume of 234,100 shares, the days-to-cover ratio is currently 11.1 days. Approximately 8.6% of the shares of the company are sold short. View Syros Pharmaceuticals' Current Options Chain.
Who are some of Syros Pharmaceuticals' key competitors?
Some companies that are related to Syros Pharmaceuticals include NextCure (NXTC), Axsome Therapeutics (AXSM), Constellation Pharmaceuticals (CNST), Amphastar Pharmaceuticals (AMPH), Amneal Pharmaceuticals (AMRX), Dova Pharmaceuticals (DOVA), Eagle Pharmaceuticals (EGRX), Vanda Pharmaceuticals (VNDA), Rocket Pharmaceuticals (RCKT), CannTrust (CNTTF), ZIOPHARM Oncology (ZIOP), Principia Biopharma (PRNB), TherapeuticsMD (TXMD), TG Therapeutics (TGTX) and Organogenesis (ORGO).
What other stocks do shareholders of Syros Pharmaceuticals own?
Who are Syros Pharmaceuticals' key executives?
Syros Pharmaceuticals' management team includes the folowing people:
- Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)
- Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)
- Dr. David A. Roth, Chief Medical Officer (Age 56)
- Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)
- Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board
When did Syros Pharmaceuticals IPO?
(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Syros Pharmaceuticals' major shareholders?
Syros Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (10.92%), Nikko Asset Management Americas Inc. (10.92%) and Tower Research Capital LLC TRC (0.01%). Company insiders that own Syros Pharmaceuticals stock include Jeremy P Springhorn, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch. View Institutional Ownership Trends for Syros Pharmaceuticals.
Which institutional investors are buying Syros Pharmaceuticals stock?
SYRS stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and Tower Research Capital LLC TRC . Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.
How do I buy shares of Syros Pharmaceuticals?
Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Syros Pharmaceuticals' stock price today?
One share of SYRS stock can currently be purchased for approximately $5.00.
How big of a company is Syros Pharmaceuticals?
Syros Pharmaceuticals has a market capitalization of $212.20 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals.
What is Syros Pharmaceuticals' official website?
How can I contact Syros Pharmaceuticals?
Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]
MarketBeat Community Rating for Syros Pharmaceuticals (NASDAQ SYRS)
MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
